medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The impact of genome-wide histocompatibility on liver transplantation outcomes

Semenova M[1], Liukkonen V[2,3], Markkinen S[1], Färkkilä M[2], Nordin A[4], Partanen J[1], Åberg F[4], Hyvärinen K[1*]

1. *Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland*
2. *University of Helsinki, Faculty of Medicine, Helsinki, Finland*
3. *North Carelia Central Hospital, Gastroenterology, Joensuu, Finland*
4. *Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland*

Short title: Genome-wide mismatches in liver transplantation

Corresponding author:

Kati Hyvärinen, PhD, Associate professor

Finnish Red Cross Blood Service

Research and Development

Biomedicum Helsinki 1, Haartmaninkatu 8, 00290 Helsinki, FINLAND

Phone +358 40 920 3083

kati.hyvarinen@bloodservice.fi

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abbreviations

aHR, adjusted hazard ratio

AR, Acute rejection

CI, Confidence interval

CHR, Chromosome

DNA, Deoxyribonucleic acid

DSA, Donor-specific antibody

eQTL, Expression quantitative trait loci

FDR, False discovery rate

GSA, Global screening array

HLA, Human leukocyte antigen

HSCT, hematopoietic stem cell transplantation

IQR, Interquartile range

LCL, Lateral collateral ligament

LT, Liver transplantation

MAF, Minor allele frequency

MD, Multi-Disease

MHC, Major histocompatibility complex

NA, Not available

POS, Position

QC, Quality control

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT

Liver transplantation (LT) is the standard treatment for end-stage liver disease. The role of human leukocyte antigen (HLA) matching in LT remains unclear. Immunologic allograft injury and rejection continue to be concerns, especially when minimizing immunosuppression. While HLA matching currently has no established role in LT, non-HLA compatibility has attracted increased attention.

We compared 666 LT recipient-donor pairs and identified genomic mismatches outside HLA segment in different protein groups and 40 common gene deletions. We evaluated the associations with LT outcomes using adjusted Cox models.

Quartiles of missense variants coding for all proteins were associated with late rejection with an adjusted hazard ratio (aHR) 0.812 (95% confidence interval [CI]: 0.674–0.977, P-value 0.028). Deletion mismatches tagged by rs11985201 and rs2342606 were associated with AR with aHR 1.483 (95% CI: 1.066–2.062, P-value 0.019) and aHR 1.373 (95% CI: 1.011–1.865, P-value 0.042), respectively. Deletion mismatch in rs2174926 was associated with graft loss with aHR 2.332 (95% CI: 1.145–4.752, P-value 0.020) and in rs1944862 with late rejection with aHR 2.341 (95% CI: 1.326–4.130, P-value 0.003). False detection rates <0.05 were not reached.

In conclusion, genome-wide mismatches may contribute to LT complications. However, robust large-scale studies are essential for validation.

Keywords

Acute rejection, late rejection, graft loss, overall survival, genome-wide incompatibility.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION

Liver transplantation (LT) is the standard treatment for end-stage liver disease, acute liver failure and selected liver cancers. Survival after LT has improved in recent years, and more than 60% of recipients now survive over 10 years[1]. With modern immunosuppression regimens, immunological complications, including acute rejection (AR) or chronic rejection, rarely lead to graft loss, even though late AR has been associated with inferior graft and recipient survival[2]. Recognition of the potential role of donor-specific antibodies (DSA)[3], especially under immunosuppression minimization, and reports of subclinical immunological damage and fibrosis in liver allografts[4] have revived interest in immunology in recent years, but majority of graft losses results from non-immunological reasons[5].

Cancer, cardiovascular events, renal failure and infections are the major reasons for mortality after LT and immunosuppressive medication predisposes recipients to such events[5]. Thus, minimizing immunosuppression to improve survival has become a major target in post-LT management[6]. As the risk of complications varies between individuals, individualized approach to immunosuppression management could improve post-LT outcomes.

The significance of human leucocyte antigens (HLA) is well-understood in hematopoietic stem cell transplantation (HSCT)[7] and kidney transplantation[8]. In addition, in the last decade, mismatches between recipient and donor in genes located outside the HLA segment has emerged as a novel histocompatibility factor in HSCT[9,10] and kidney transplantation[11–15]. For example, according to a recent study, the kidney allograft survival was influenced by incompatibility in genes outside HLA[12]. In another recent study, researchers stated that genomic mismatch at *LIMS1* locus was associated with rejection of the kidney allograft[11].

The effect of HLA compatibility on LT outcomes is still debated with studies showing mixed outcomes[16,17] and matching is not used in organ allocation. There is a clear lack of data about the role of genome-wide compatibility in LT. Identifying novel risk factors for immunological and other important post-LT complications could help with risk stratification and individualized management[18].

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

In the present study, we analyzed the association of genome-wide incompatibility and time to any AR, late AR, graft loss and death in a LT cohort of 666 recipient-donor pairs to identify novel genetic risk factors for LT outcomes.

STUDY SUBJECTS AND METHODS

Study cohort and design

The study conforms to the principles of the Declaration of Helsinki and has been approved by the ethics committee of Helsinki University Hospital (HUS/155/2021), the Finnish Medicines Agency Fimea (FIMEA/2021/004031), and Abdominal Center, Helsinki University Hospital (HUS/155/2021/68).

The characteristics of the recipients are described in **Tables 1 and 2**. The flow chart of the study cohort is presented in **Figure 1**. In total, 894 liver transplantation recipients who had received a liver transplant between years 2000–2018 and their respective first transplantation donors were included in the present study. The DNA samples of both recipients and donors were extracted from whole blood samples at Finnish Red Cross Blood Service, Helsinki. After exclusion of individuals lacking DNA samples, the whole study cohort was divided into three different cohorts: Genotyping cohort 1 consisting of 286 donors, Genotyping cohort 2 including 30 recipients and 125 donors, and Genotyping cohort 3 comprising 1202 individuals. Individuals who failed passing the quality control (QC), who's pair was missing genotyping information and those younger than 18 years old were excluded.

All ARs were biopsy confirmed according to BANFF-scheme[19]. Late rejection was determined as AR diagnosed over 90 days after the transplantation. Primary or secondary LT indication of primary sclerosing cholangitis, primary biliary cholangitis, or autoimmune hepatitis was categorized as autoimmune liver disease.

Genotyping and genotype imputation

Supplementary Figure 1 presents the flow of genetic variants in pre- and post-imputation processes. Genotyping was performed at the Finnish Institute of Molecular Medicine, Helsinki, Finland. Cohort I was genotyped using Illumina Infinium™ Global

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Screening Array (GSA)-24 v3.0 BeadChip + Multi-Disease (MD) drop-in customized with 34,191 Finnish variants. Cohorts II and III were genotyped using Illumina Infinium™ GSA-24 v2.0 + MD bead chip. Prior to genotype imputation, results in build GRCh37 were lifted over to the GRCh38[20]. Genotype imputation was performed with Beagle v4.1 program utilizing THL Biobank's SISu v3 reference panel according to Palta *et al*.[21] https://www.protocols.io/view/genotype-imputation-workflow-v3-0-xbgfijw?step=4&comment_id=86624. In post-imputation QC, individuals with missing genotype >5% and variants with missing data rate >10%, minor allele frequency (MAF) <1%, and imputation INFO score <0.6 were excluded. In total, 8,706,949 common variants were available for the analyses.

HLA imputation and eplet mismatches

Imputation of alleles of HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, and -DPB1 genes was performed according to Ritari *et al*.[22] utilizing R package HIBAG in RStudio version 3.6.3. (https://github.com/FRCBS/HLA-imputation).

HLA eplet mismatches between recipients and donors were calculated for imputed HLA-A, -B, -C, -DRB, -DQB, and -DPB alleles utilizing HLAMatchmaker (http://www.epitopes.net/)[23]. HLA-A, -B, and -C alleles were matched using a ABC Eplet Matching Program V4.0 and HLA-DRB, -DPB, -DQA, and -DQB alleles were matched using a DRDQDP Eplet Matching Program V3.1 program. The programs were downloaded from http://www.epitopes.net/downloads.html.

Missense variant mismatch analyses

Prior to performing mismatch analyses, the variants coded on major histocompatibility complex (MHC) region on chromosome 6 and both sex chromosomes were excluded, leaving only autosomal non-HLA variants in the dataset. **Figure 2** shows the flow of variants. Functional annotation of variants was performed with Ensemble Variant Effect Predictor[24] release 106 (https://www.ensembl.org/info/docs/tools/vep/script/index.html). Transcripts for all, transmembrane and secreted proteins, transmembrane proteins, and liver-related proteins were retrieved from UniProt 84 (https://www.uniprot.org/). Filtering operator

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

"consequence is missense_variants" was utilized. Term missense variant refers to a nucleotide polymorphism changing the encoded amino acid in the protein.

The query strings for different protein groups were as follows:

1. Transmembrane and secreted proteins

(annotation:(type:transmem) OR locations:(location:"Secreted [SL-0243]") OR keyword:"Transmembrane [KW-0812]") AND reviewed:yes AND organism:"Homo sapiens (Human) [9606]"

2. Transmembrane proteins

(annotation:(type:transmem) OR keyword:"Transmembrane [KW-0812]") AND reviewed:yes AND organism:"Homo sapiens (Human) [9606]"

3. Liver-related proteins

annotation:(type:"tissue specificity" liver) AND reviewed:yes AND organism:"Homo sapiens (Human) [9606]"

We compared recipient and donor genomes pairwise and calculated missense variant mismatch sums between the genomes for four different protein groups: missense variants coding for 1) all proteins, 2) transmembrane and secreted proteins, 3) transmembrane proteins only, 4) liver-related proteins.

Cox proportional hazards models were utilized to investigate the effect of missense variant mismatches on time to AR, late rejection, graft loss, and overall survival. We analyzed both missense variant mismatch sums and quartiles of missense variant mismatch sums in each protein group. All models were adjusted with recipient and donor sex, recipient and donor age, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease, and initial calcineurin inhibitor type. Censoring occurred on the end of the follow up time, re-transplantation, or death. Kaplan-Meier plots were used to visualize the AR-, late rejection-, graft loss-, death-free survival of the recipients.

Deletion analyses

The study protocol presented by Markkinen *et al*.[25] was followed. 40 deletion-tagging variants and their frequencies in the study cohort are presented in **Supplementary Table S1**. Deletion mismatch was defined as a situation where recipient is

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

homozygous for a deletion-tagging allele and receives a liver from a donor that is either homozygous or heterozygous for the reference allele.

We analyzed the effect of homozygous mismatches in 40 deletion-tagging variants using adjusted Cox proportional hazards models. Censoring occurred on re-transplantation, death or end of the follow up time. The dependent variables were time to any AR, late AR, graft loss and death. We investigated the deletion-tagging variant mismatches separately and quartiles of sum of deletion-tagging variant mismatches. All models were adjusted with donor and recipient age, donor and recipient sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease and initial calcineurin inhibitor type. Kaplan-Meier survival curves were used to visualize the rejection-, graft loss- and death-and late rejection-free survival of the recipients. Full Cox models and Kaplan-Meier plots (**Figures 3–6**) are presented for variants with nominal P-values <0.05 and with n value of homozygous deletion-tagging variant mismatches >10 (**Supplementary Tables S1, S6–S9**).

Expression quantitative trait loci results and regulatory element annotations

Expression quantitative trait loci (eQTL) results were searched for four deletion-tagging variants rs11985201, rs2342606, rs2174926, and rs1944862, all with p-values <0.05 before correction for multiple comparisons, using FIVEx[26] https://fivex.sph.umich.edu/ and eQTLGen phase I[27] https://www.eqtlgen.org/phase1.html. Regulatory elements were identified utilizing RegulomeDB[28] database https://regulomedb.org/regulome-search/. The Regulome DB rank varies from 1(a-f)–7 and the score ranges from 0–1 (with 1 as the most reliable result). Regulatory motifs and annotations were also explored using Haploreg[29] v4.2 tool https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php.

Other statistical analyses

Normality of variable distributions was evaluated using the Shapiro-Wilk normality test. In **Tables 1 and 2**, the variation between outcome groups was analyzed using the Pearson's chi-square test for categorical data (recipient gender, primary indication,

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

autoimmune liver disease and initial calcineurin inhibitor type) and the nonparametric Mann-Whitney U-test for nonnormally distributed data (recipient age, follow-up time, cold ischemia time, HLA eplet mismatch sum, HLA I eplet mismatch sum and HLA II eplet mismatch sum). P-values <0.05 were considered statistically significant.

To counteract the multiple comparison problem in mismatch analyses, false discovery rate (FDR) was determined and FRD <0.05 was considered statistically significant.

All analyses were performed using in R v3.6.3[30].

Data and code availability

Individual genotype data are not publicly available due to restrictions issued by the ethical committee and current legislation in Finland that do not allow the distribution of pseudonymized personal data, including genetic and clinical data.

Analysis scripts are available at https://github.com/FRCBS XXXXXX.

RESULTS

Characteristic of the study population

Characteristics of the recipients in the study population are presented in **Tables 1 and 2**. During the follow up time (median interquartile range [IQR] 7 [4–12] years), of the 666 recipients, 42% experienced AR, 15% late rejection, 6% graft loss, and 24% died. Women had AR more often than men (51% vs. 49%, P-value 0.029). The median (IQR) time to AR was 21 (11–87) days. The median (IQR) time to late rejection was 11 (5–23) months. The median (IQR) time to graft loss was 34 (4–77) months and the median (IQR) time to death was 3 (1–9) years.

Missense variant mismatch analyses

After the exclusion of sex chromosomes, MHC region, and non-missense variants, 28,225 missense variants were available for the mismatch analyses. Of these missense variants, 9,337 variants code for both transmembrane and secreted proteins, 6,963 variants for transmembrane proteins only, and 3,199 variants for liver-

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

related proteins (**Figure 2**). **Table 3** shows results from Cox proportional hazards models, both the sums and quartiles of missense variant mismatches. **Supplementary figure S2** displays the effect of quartiles of missense variant mismatches of all proteins on late rejection -free survival. **Supplementary Figure S3** shows the effect of quartiles of missense variant mismatches of transmembrane proteins only on graft loss -free survival. All models were adjusted with recipient and donor age, recipient and donor sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease, and initial calcineurin inhibitor type. We observed an association between both the sum and quartiles of mismatches in missense variants in all proteins and time to late rejection (HR 0.998, 95% CI 0.996–0.999, P-value 0.011 and HR 0.812, 95% CI 0.674–0.977, P-value 0.028, respectively).

Deletion analyses

The results from adjusted Cox proportional hazards models showed that a deletion mismatch in variants rs11985201 and rs2342606 was associated with time to AR with HR 1.483 (95% CI: 1.066–2.062, P-value 0.019, **Supplementary Table S6, Figure 3** and HR 1.373 (95% CI: 1.011–1.865, P-value 0.042, **Supplementary Table S7**, **Figure 4**), respectively. In addition, time to late rejection was associated with deletion mismatch in rs1944862 with HR 2.341 (95% CI: 1.326–4.130, P-value 0.003, **Supplementary Table S8**, **Figure 5**) and time to graft loss with a deletion mismatch in rs2174926 with HR 2.332 (95% CI: 1.145–4.752, P-value 0.020, **Supplementary Table S9**, **Figure 6**). However, the P-values did not reach the level of statistical significance FDR <0.05.

Supplementary Tables S2–S5 summarize the results from adjusted Cox proportional hazards models for the 40 deletion-tagging variants separately for time to AR, late rejection, graft loss and overall survival. **Supplementary Figures S4–S7** display the effect of quartiles of overall deletion mismatch sums on LT endpoints. No association was found between the quartiles of overall deletion mismatch sums and LT endpoints.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Expression quantitative trait loci analyses and regulatory element annotation

We searched public databases to obtain information about regulatory functions for deletion-tagging variants rs11985201, rs2342606, rs2174926, and rs1944862.

Table 4 shows the *cis*-eQTL results for deletion-tagging variants rs11985201, rs2342606, rs1944862, and rs2174926 in the FIVEx and eQTLGen phase I databases. Using FIVEx browser, we found rs2342606 to be associated with increased expression levels of TMEM254 antisense RNA 1 (*TMEM252-AS1*) gene in several different tissues. In eQTLGen phase I database, variant rs2342606 associated with altered expression of following genes: *TMEM254*, *TMEM254-AS1*, *FAM22B*, *RP11-119F19.2*, *FAM213A*, *SFTPD*, *RP11-137H2.4,* and *RP11-506M13.3*.

In FIVEx, rs11985201 associated with decreased expression levels of olfactory receptor family 4 subunit C member 6 (*OR4C6*) protein coding gene in lateral collateral ligament tissue. In eQTLGen phase I browser, we found variant rs11985201 to be associated with decreased expression level of indoleamine 2,3-dioxygenase 1 (*IDO1*) gene in blood cells.

Regulome DB and HaploReg tools were utilized for identifying regulatory elements (**Table 5**). Two of the variants, rs11985201 and rs2174926, got a high Regulome DB rank and score, which are both prediction scores informing the quality of supporting evidence in literature for regulatory role of variants. Using HaploReg v4.2 database, altered transcription factor regulatory motifs were found for variants rs11985201, rs2174926, and rs1944862. Deletion-tagging variant rs11985201 associated with alteration in zinc-finger transcription factor (INSM1) and nuclear transcription factor Y (NF-Y). Deletion-tagging variant rs2174926 was found to affect the forkhead box J2 (Foxj2), forkhead box L1 (Foxl1), and forkhead box P1 (Foxp1) transcription factors. Deletion-tagging variant rs1944862 associated with alteration in forkhead box A (Foxa) and zinc finger and btb domain containing 33 (ZBTB33) transcription factors.

DISCUSSION

In the present study, we investigated the association between LT endpoints and genome-wide mismatches in 666 LT recipients-donor pairs. We inspected mismatches in missense variants changing the amino acid sequence of the encoded protein and,

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

additionally, in 40 common deletion-tagging variants. In deletion analyses, deletion-tagging variants rs11985201, rs2342606, rs2174926 and rs1944862 were associated with an increased risk of negative LT outcomes and could be novel histocompatibility factors in LT. However, the observed P-values did not pass FDR <0.05 level, hence further validation is needed.

Genetic differences between recipients and donors have been identified as an important factor in allograft rejection and has been a topic of active research over the last decade[11–13]. The importance of matching of HLA alleles has been well-established in kidney and hematopoietic stem cell transplantations[31]. However, the importance of HLA matching for LT recipients and donors remains controversial[32–35]. A recent study found that mismatch in HLA-A was associated with an increased risk of allograft loss after LT[33] while another meta-analysis found a significant association between HLA-C matching and increased risk of AR in LT[36]. However, an study conducted by Muro *et al*. indicates that HLA matching does not yield better LT outcomes and that poorer HLA matching showed better allograft survival and decreased rejection incidence[34]. In the present study the HLA I class eplet matchings in certain deletion-tagging variants associated with a higher risk of AR. However, the p-values did not reach the level of statistical significance FDR <0.05. Studies investigating the importance of non-HLA genetic factors in LT outcomes remain scarce.

Whole genome-wide incompatibility between recipient and donor has emerged as a potential risk factor in kidney transplantation[11–14]. A study conducted by Reindl-Schwaighofer *et al*. in 2019 demonstrated the effect of genome-wide genetic incompatibility between recipients and donors on graft survival in kidney transplantation[12]. The results indicated that mismatches in transmembrane and secreted proteins were associated with an increased risk of graft loss independently of HLA[12]. Markkinen *et al*. in 2022 reported that an increasing mismatch sum in kidney-related proteins increased the risk of time to AR after kidney transplantation[25]. In the present study, we found statistically significant association between time to late rejection and missense variant mismatches in all proteins group. The effect size, however, was small, suggesting limited practical application.

Another recent study found an association between kidney allograft rejection and genomic mismatch at *LIMS1* locus[11]. The results published by Steers *et al.* in 2019

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

were not confirmed in the Finnish patients by Markkinen *et al.* who instead found an association between AR and mismatch in deletions at the complement factor H related protein (CFHR) locus[25]. The present study did not find associations with LIMS or CFHR deletions. Instead, we found associations between four other deletion-tagging variants and outcomes of LT. All these results, together with those of HSCT[9], suggest that deletion mismatches in general predispose to graft incompatibility but predominant deletions vary between transplant types and populations. Clearly, more studies on the role of deletion mismatches and how they lead to higher rejection risk are needed. We must note that LT differs from other transplantations as the liver has a tolerogenic microenvironment that enables it to regulate local immune responses[37] that may result in a higher tolerance against immunogenetic incompatibility in LT as compared to other transplantations.

Whenever a recipient receives an organ that possesses protein structures foreign to the recipient due to e.g., common deletions, there is a possibility of an immune reaction that may lead to negative post-LT outcomes. Therefore, when a recipient with a homozygous deletion receives a liver from a donor lacking the particular homozygous deletion, the immune system of the recipient identifies these protein structures on the liver as foreign and causes the production of DSAs that may mitigate antibody-mediated rejection. In addition, the lack of certain important immune regulatory proteins, such as CFHR1 may have a negative effect by itself.

Furthermore, genetic variants, and deletions as well, can regulate expression levels of genes that can be located close to or at longer distances to the variant. These eQTL effects can be screened from public databases. rs11985201 tags the deletion of metallopeptidase *ADAM3A* and *ADAM5P* pseudogenes. However, neither ADAM3A or ADAM5P are expressed in liver[38,39]. In addition, the variant affects binding motifs for INSM and NF-Y factors downregulates IDO1 expression. rs2342606 tags the deletion of *LOC642521/LOC642538* genes but does not affect any known binding motifs. There is a limited information on these genes, but the LOC642521 seems to be linked with a nuclear DNA-binding protein[41]. Variants rs11985201 and rs1944862 were included in the top 15,000 methylation quantitative train loci identified in human liver[42], meaning that they are associated with DNA methylation – a process that can change the activity of certain DNA regions by either inhibiting or promoting the activity of transcription factors.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Strengths and limitations of the study may be observed. To be able to collect a reasonable cohort size from a single center, the LTs in the present study are from a relatively long period, extending 19 years in total. We compensated this potential effect by selecting the transplantation year as one of the covariates. The size of the cohort albeit one of the largest published so far for genome analyses included only 666 recipient-donor pairs, which enables the recognition of only relatively large effect sizes for the p-values to pass the correction for multiple comparisons. Larger collaborative studies are warranted to overcome the power issue. This study is the first large-scale single-center study investigating the impact of genome-wide compatibility on time to AR, late rejection, graft loss and overall survival in LT. Single-center study in the relatively homogeneous Finnish population should limit heterogeneity in patient demographics, treatments, and genetic background. In addition, the recipients were not affected by immunization from or treatments of previous liver allografts as only the first LTs were included in the study cohort.

In conclusion, genetic incompatibility between recipients and donors on a whole-genome level may be a significant histocompatibility factor affecting LT outcomes. Robust large-scale studies are required to confirm the role of genome-wide mismatches and common variants in LTs.

AUTHOR CONTRIBUTION

MS, SM, JP, KH designed the study. MS and KH carried out the genome data analysis. VL, FÅ, AN, MF provided clinical data and clinical expertise. MS, SM, JP, FÅ, KH interpreted the results. MS and VL drafted the manuscript. All authors read, accepted and contributed to the final version of the manuscript.

ACKNOWLEDGEMENTS

The reference data for genotype imputation was obtained from THL Biobank (study number: BB2019_12). We thank all study participants for their generous participation in biobank research.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

DISCLOSURE AND FUNDING

The authors of this manuscript have no conflicts of interest to disclose.

The study was partially supported by funding from the Government of Finland VTR funding (to FRCBS). FÅ received grants from Mary and Georg Ehrnrooth Foundation and Medicinska Understödsföreningen Liv och Hälsa.

SUPPORTING INFORMATION STATEMENT

Supplementary information may be found online.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES

1. ELTR. Evolution of LTs in Europe - European Liver Transplant Registry. Accessed May 24, 2024. http://www.eltr.org/spip.php?article152

2. Jadlowiec CC, Morgan PE, Nehra AK, et al. Not All Cellular Rejections Are the Same: Differences in Early and Late Hepatic Allograft Rejection. *Liver Transplant*. 2019;25(3):425-435. doi:10.1002/LT.25411

3. O'Leary JG, Cai J, Freeman R, et al. Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts. *Am J Transplant*. 2016;16(2):603-614. doi:10.1111/AJT.13476

4. Vionnet J, Miquel R, Abraldes JG, et al. Non-invasive alloimmune risk stratification of long-term liver transplant recipients. *J Hepatol*. 2021;75(6):1409-1419. doi:10.1016/j.jhep.2021.08.007

5. Watt KDS, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of Causes and Risk Factors for Mortality Post Liver Transplant: Results of the NIDDK Long Term Follow-up Study. *Am J Transplant*. 2010;10(6):1420. doi:10.1111/J.1600-6143.2010.03126.X

6. Charlton M, Levitsky J, Aqel B, et al. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. *Transplantation*. 2018;102(5):727-743. doi:10.1097/TP.0000000000002147

7. Fürst D, Müller C, Vucinic V, et al. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. *Blood*. 2013;122(18):3220-3229. doi:10.1182/BLOOD-2013-02-482547

8. Teven S, Akemoto KT, Erasaki AIT, Jertson AWG, Ichael JM, Ecka C. Twelve Years' Experience with National Sharing of HLA-Matched Cadaveric Kidneys for Transplantation. *http://dx.doi.org/101056/NEJM200010123431504*. 2009;343(15):1078-1084. doi:10.1056/NEJM200010123431504

9. McCarroll SA, Bradner JE, Turpeinen H, et al. Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. *Nat Genet*. 2009;41(12):1341-1344. doi:10.1038/ng.490

10. Ritari J, Hyvärinen K, Koskela S, et al. Computational Analysis of HLA-presentation of Non-synonymous Recipient Mismatches Indicates Effect on the Risk of Chronic Graft-vs.-Host Disease after Allogeneic HSCT. *Front Immunol*. 2019;10(JULY). doi:10.3389/fimmu.2019.01625

11. Steers NJ, Li Y, Drace Z, et al. Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection . *N Engl J Med*. 2019;380(20):1918-1928. doi:10.1056/nejmoa1803731

12. Reindl-Schwaighofer R, Heinzel A, Kainz A, et al. Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort. *Lancet*. 2019;393(10174):910-917. doi:10.1016/S0140-6736(18)32473-5

13. Mesnard L, Muthukumar T, Burbach M, et al. Exome Sequencing and

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Prediction of Long-Term Kidney Allograft Function. *PLoS Comput Biol*. 2016;12(9):e1005088. doi:10.1371/journal.pcbi.1005088

14. Pineda S, Sigdel TK, Chen J, Jackson AM, Sirota M, Sarwal MM. Novel non-histocompatibility antigen mismatched variants improve the ability to predict antibody-mediated rejection risk in kidney transplant. *Front Immunol*. 2017;8(DEC):1687. doi:10.3389/FIMMU.2017.01687

15. Zhang Z, Menon MC, Zhang W, et al. Genome-wide non-HLA donor-recipient genetic differences influence renal allograft survival via early allograft fibrosis. *Kidney Int*. 2020;98(3):758-768. doi:10.1016/j.kint.2020.04.039

16. Balan V, Ruppert K, Demetris AJ, et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: Results of the national institute of diabetes and digestive and kidney diseases liver transplantation database. *Hepatology*. 2008;48(3):878-888. doi:10.1002/HEP.22435

17. Navarro VJ, Herrine S, Katopes C, Colombe B, Spain CV. The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: An analysis of the OPTN database. *Liver Transplant*. 2006;12(4):652-658. doi:10.1002/LT.20680

18. Thomson AW, Vionnet J, Sanchez-Fueyo A. Understanding, predicting and achieving liver transplant tolerance: from bench to bedside. *Nat Rev Gastroenterol Hepatol*. 2020;17(12):719-739. doi:10.1038/s41575-020-0334-4

19. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. *Hepatology*. 1997;25(3):658-663. doi:10.1002/HEP.510250328

20. Pärn K, Fontarnau JN, Isokallio MA, et al. Genotyping chip data lift-over to reference genome build GRCh38/hg38. Accessed July 4, 2022. https://www.protocols.io/view/genotyping-chip-data-lift-over-to-reference-genome-n2bvjmbpvk5w/v2?version_warning=no

21. Pärn K, Isokallio MA, Fontarnau JN, Palotie A, Ripatti S, Palta P. *Genotype Imputation Workflow v3.0 V.2*.; 2019. https://www.protocols.io/view/genotype-imputation-workflow-v3-0-xbgfijw?step=4&comment_id=86624

22. Ritari J, Hyvärinen K, Clancy J, FinnGen, Partanen J, Koskela S. Increasing accuracy of HLA imputation by a population-specific reference panel in a FinnGen biobank cohort. *NAR genomics Bioinforma*. 2020;2(2):lqaa030. doi:10.1093/nargab/lqaa030

23. Duquesnoy RJ, Askar M. HLAMatchmaker: A Molecularly Based Algorithm for Histocompatibility Determination. V. Eplet Matching for HLA-DR, HLA-DQ, and HLA-DP. *Hum Immunol*. 2007;68(1):12-25. doi:10.1016/J.HUMIMM.2006.10.003

24. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. *Genome Biol*. 2016;17(1):1-14. doi:10.1186/S13059-016-0974-4/TABLES/8

25. Markkinen S, Helanterä I, Lauronen J, Lempinen M, Partanen J, Hyvärinen K. Mismatches in Gene Deletions and Kidney-related Proteins as Candidates for Histocompatibility Factors in Kidney Transplantation. *Kidney Int reports*.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

2022;7(11):2484-2494. doi:10.1016/J.EKIR.2022.08.032

26. Kwong A, Boughton AP, Wang M, et al. FIVEx: an interactive eQTL browser across public datasets. *Bioinformatics*. 2022;38(2):559. doi:10.1093/BIOINFORMATICS/BTAB614

27. Võsa U, Claringbould A, Westra HJ, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat Genet 2021 539*. 2021;53(9):1300-1310. doi:10.1038/S41588-021-00913-Z

28. Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res*. 2012;22(9):1790. doi:10.1101/GR.137323.112

29. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res*. 2012;40(Database issue):D930. doi:10.1093/NAR/GKR917

30. R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna. - References - Scientific Research Publishing. Published 2022. Accessed January 8, 2024. https://www.scirp.org/reference/referencespapers?referenceid=3456808

31. Opelz G, Wujciak T, Döhler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. *Rev Immunogenet*. 1999;1(3):334-342. Accessed August 6, 2023. https://europepmc.org/article/med/11256424

32. Balan V, Ruppert K, Demetris AJ, et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. *Hepatology*. 2008;48(3):878-888. doi:10.1002/HEP.22435

33. Bricogne C, Halliday N, Fernando R, et al. Donor–recipient human leukocyte antigen A mismatching is associated with hepatic artery thrombosis, sepsis, graft loss, and reduced survival after liver transplant. *Liver Transplant*. 2022;28(8):1306-1320. doi:10.1002/LT.26458

34. Muro M, López-Álvarez MR, Campillo JA, et al. Influence of human leukocyte antigen mismatching on rejection development and allograft survival in liver transplantation: Is the relevance of HLA-A locus matching being underestimated? *Transpl Immunol*. 2012;26(2-3):88-93. doi:10.1016/J.TRIM.2011.11.006

35. Muro M, Legaz I. Importance of human leukocyte antigen antibodies and leukocyte antigen/killer-cell immunoglobulin-like receptor genes in liver transplantation. *World J Gastroenterol*. 2023;29(5):766-772. doi:10.3748/WJG.V29.I5.766

36. Kok G, Ilcken EF, Houwen RHJ, et al. The Effect of Genetic HLA Matching on Liver Transplantation Outcome: A Systematic Review and Meta-Analysis. *Ann Surg Open*. 2023;4(3):e334. doi:10.1097/AS9.0000000000000334

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

37. Demetris AJ, Bellamy COC, Gandhi CR, Prost S, Nakanuma Y, Stolz DB. Functional Immune Anatomy of the Liver—As an Allograft. *Am J Transplant*. 2016;16(6):1653-1680. doi:10.1111/AJT.13749

38. AGCOH. ADAM3A (ADAM metallopeptidase domain 3A (pseudogene)). Published June 1, 2014. Accessed October 6, 2023. https://atlasgeneticsoncology.org/gene/53975/adam3a-(adam-metallopeptidase-domain-3a-(pseudogene))/

39. AGCOH. ADAM5 (ADAM metallopeptidase domain 5 (pseudogene)). Published November 1, 2014. Accessed October 6, 2023. https://atlasgeneticsoncology.org/gene/60138/

40. Lichtinghagen R, Michels D, Haberkorn CI, et al. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. *J Hepatol*. 2001;34(2):239-247. doi:10.1016/S0168-8278(00)00037-4

41. Seno A, Kasai T, Ikeda M, et al. Characterization of Gene Expression Patterns among Artificially Developed Cancer Stem Cells Using Spherical Self-Organizing Map. *Cancer Inform*. 2016;15:163. doi:10.4137/CIN.S39839

42. Bonder MJ, Kasela S, Kals M, et al. Genetic and epigenetic regulation of gene expression in fetal and adult human livers. *BMC Genomics*. 2014;15(1). doi:10.1186/1471-2164-15-860

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

FIGURE LEGENDS

Figure 1. Flow of the study population. Enrolling and exclusion of the liver transplantation recipients and donors. DNA, deoxyribonucleic acid; QC, quality control.

Figure 2. Flow of genetic variants. HLA, human leukocyte antigen; MHC, major histocompatibility complex.

Figure 3. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs11985201 mismatch on acute rejection-free survival. The blue curve represents the 'deletion mismatch' group with recipients who were homozygous for a deletion-tagging allele G and received a transplant from a donor with TG or TT**.** The orange curve represents the 'no mismatch' group. Under the survival curve, a risk table is displayed with the number of recipients at risk of acute rejection. The presented hazard ratio, confidence intervals and P-value were calculate using Cox proportional hazards model. The model was adjusted with recipient and donor age, recipient and donor sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease and initial calcineurin inhibitor type. Deletion-tagging variant: rs11985201, Affected genes: ADAM metallopeptidase domain 3A (pseudogene) and domain 5 (pseudogene) (*ADAM3A/ADAM5P*). CI, confidence interval; HR, hazard ratio.

Figure 4. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs2342606 mismatch on acute rejection-free survival. The blue curve represents the 'deletion mismatch' group with recipients who were homozygous for a deletion-tagging allele T and received a transplant from a donor with TC or CC**.** The orange curve represents the 'no mismatch' group. Under the survival curve, a risk table is displayed with the number of recipients at risk of acute rejection. The presented hazard ratio, confidence intervals and P-value were calculate using Cox proportional hazards model. The model was adjusted with recipient and donor age, recipient and donor sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease and initial calcineurin inhibitor type. Affected genes: C1D nuclear receptor corepressor pseudogene 3 (*LOC642521*) and C1D nuclear receptor corepressor pseudogene 2 (*LOC642538*). CI, confidence interval; HR, hazard ratio.

Figure 5. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs1944862 mismatch on graft loss-free survival. The blue curve represents the 'deletion mismatch' group with recipients who were homozygous for a deletion-tagging allele A and received a transplant from a donor with AG or GG**.** The orange curve represents the 'no mismatch' group. Under the survival curve, a risk table is displayed with the number of recipients at risk of late rejection. The presented hazard ratio, confidence intervals and P-value were calculate using Cox proportional hazards model. The model was adjusted with recipient and donor age, recipient and donor sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease and initial calcineurin inhibitor type. Affected

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

gene: olfactory receptor family 4 subunit (OR4P1P), pseudogene,. CI, confidence interval; HR, hazard ratio.

Figure 6. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs2174926 mismatch on graft loss-free survival. The blue curve represents the 'deletion mismatch' group with recipients who were homozygous for a deletion-tagging allele A and received a transplant from a donor with AG or GG**.** The orange curve represents the 'no mismatch' group. Under the survival curve, a risk table is displayed with the number of recipients at risk of graft loss. The presented hazard ratio, confidence intervals and P-value were calculate using Cox proportional hazards model. The model was adjusted with recipient and donor age, recipient and donor sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease and initial calcineurin inhibitor type. Affected gene: hypothetical protein (*LOC442434*). CI, confidence interval; HR, hazard ratio.

598 **Table 1. Characteristics of the study population for acute and late rejection groups.**

Characteristic	All recipients	Rejection	No rejection	P*	Late rejection	No late rejection	P*
n (%)	666 (100)	277 (42)	389 (58)		97 (15)	569 (85)	
Age (median, range)	54 (18–74)	52 (18–73)	55 (18–74)	<0.001[a]	52 (18–73)	54 (45–61)	0.027[a]
Gender, n (%)				0.029[b]			0.135[a]
Male	359 (54)	135 (49)	224 (58)		45 (46)	314 (55)	
Female	307 (46)	142 (51)	165 (42)		52 (54)	255 (45)	
Primary indication, n (%)							
Primary sclerosing cholangitis	128 (19)	65 (23)	63 (16)	0.024[b]	21 (22)	107 (19)	0.605[b]
Alcoholic cirrhosis	124 (19)	29 (10)	95 (24)	<0.001[b]	10 (10)	114 (20)	0.033[b]
Hepatocellular carcinoma and cirrhosis	80 (12)	28 (10)	52 (13)	0.248[b]	7 (7)	73 (13)	0.161[b]
Primary biliary cirrhosis	53 (8)	27 (10)	26 (7)	0.120[b]	11 (11)	42 (7)	0.259[b]
Cryptogenic (unknown) cirrhosis	41 (6)	13 (5)	28 (7)	0.245[b]	6 (6)	35 (6)	1[b]
NASH	28 (4)	3 (1)	25 (6)	0.001[b]	2 (2)	26 (5)	0.388[b]
Autoimmune cirrhosis	28 (4)	11 (4)	17 (4)	0.955[b]	5 (5)	23 (4)	0.817[b]
Polycystic disease	20 (3)	7 (3)	13 (3)	0.706[b]	2 (2)	18 (3)	0.790[b]
Other	164 (25)	94 (34)	70 (18)	<0.001[b]	33 (34)	131 (23)	0.028[b]
Autoimmune liver disease, n (%)	223 (33)	109 (39)	114 (29)	0.009[b]	37 (38)	186 (33)	0.349[b]
Transplantation year							
2000–2005	126 (19)	66 (24)	60 (15)	0.009[b]	19 (20)	107 (19)	0.967[b]
2006–2011	208 (31)	89 (32)	119 (31)	0.736[b]	39 (40)	169 (30)	0.052[b]
2012–2018	332 (50)	122 (44)	210 (54)	0.014[b]	39 (40)	293 (51)	0.052[b]
Calcineurin inhibitor, n (%)				0.436[b]			0.193[b]
Cyclosporine	545 (82)	232 (84)	313 (80)		85 (88)	460 (81)	
Tacrolimus	108 (16)	41 (15)	67 (17)		11 (11)	97 (17)	
Data not available	13 (2)	4 (1)	9 (2)		1 (1)	12 (2)	
				Median (IQR)			
Follow–up time[c], months	82 (43–145)	97 (50–154)	73 (39–131)	0.002[a]	91 (51–149)	79 (41–141)	0.103[a]
Cold ischemia time, minutes	298 (258–357)	297 (257–336)	302 (263–366)	0.104[a]	298 (259–337)	300 (258–359)	0.671[a]

HLA eplet mismatch sum	27 (21–33)	29 (23–34)	26 (20–32)	0.002[a]	29 (24–35)	27 (21–33)	0.026[a]
HLA I eplet mismatch sum	17 (12–22)	17 (13–22)	16 (12–21)	0.022[a]	18 (13–21)	17 (12–22)	0.126[a]
HLA II eplet mismatch sum	10 (7–14)	11 (7–14)	10 (7–13)	0.032[a]	11 (8–15)	10 (7–13)	0.107[a]

HLA, human leukocyte antigen; IQR, interquartile range, NASH non-alcoholic steatohepatitis

*The significance of variation was calculated between the outcome groups.

[a]The Mann–Whitney U-test.

[b]The Pearson chi-square test

[c]Includes time to last follow-up date, re-transplantation and death.

606 **Table 2. Characteristics of the study population for graft loss and overall survival groups.**

Characteristic	All recipients	Graft loss	No graft loss	P*	Deceased	Alive	P*
n (%)	666 (100)	42(6)	624 (94)		163 (24)	503 (76)	
Age (median, range)	54 (18–74)	50 (18–64)	54 (18–743)	0.007[a]	58 (18–74)	52 (18–73)	<0.001[a]
Gender, n (%)				0.494[b]			0.543[b]
Male	359 (54)	20 (48)	339 (54)		84 (52)	275 (55)	
Female	307 (46)	22 (52)	285 (46)		79 (48)	228 (45)	
Primary indication, n (%)							
Primary sclerosing cholangitis	128 (19)	12 (29)	116 (19)	0.166[b]	23 (14)	105 (21)	0.073[b]
Alcoholic cirrhosis	124 (19)	3 (7)	121 (19)	0.077[b]	26 (16)	98 (19)	0.373[b]
Hepatocellular carcinoma and cirrhosis	80 (12)	2 (5)	78 (13)	0.212[b]	25 (15)	55 (11)	0.173[b]
Primary biliary cirrhosis	53 (8)	5 (12)	48 (8)	0.495[b]	11 (7)	42 (8)	0.624[b]
Cryptogenic (unknown) cirrhosis	41 (6)	3 (7)	38 (6)	1[b]	16 (10)	25 (5)	0.040[b]
NASH	28 (4)	0 (0)	28 (4)	0.315[b]	7 (4)	21 (4)	1[b]
Autoimmune cirrhosis	28 (4)	1 (2)	27 (4)	0.833[b]	7 (4)	21 (4)	1[b]
Polycystic disease	20 (3)	0 (0)	20 (3)	0.477[b]	2 (1)	18 (4)	0.206[b]
Other	164 (25)	16 (38)	148 (24)	0.056[b]	46 (28)	118 (23)	0.262[b]
Autoimmune liver disease, n (%)	223 (33)	20 (48)	203 (33)	0.066[b]	48 (29)	175 (35)	0.246[b]
Transplantation year							
2000–2005	126 (19)	12 (29)	114 (18)	0.148[b]	51 (32)	75 (15)	<0.001[b]
2006–2011	208 (31)	15 (36)	193 (31)	0.634[b]	58 (36)	150 (30)	0.200[b]
2012–2018	332 (50)	15 (36)	317 (51)	0.083[b]	54 (33)	278 (55)	<0.001[b]
Calcineurin inhibitor, n (%)				0.071[b]			0.393[b]
Cyclosporine	545 (82)	38 (90)	507 (81)		135 (83)	410 (82)	
Tacrolimus	108 (16)	2 (5)	106 (17)		22 (13)	86 (17)	
Data not available	13 (2)	2 (5)	11 (2)		6 (4)	7 (1)	
				Median (IQR)			
Follow–up time[c], months	82 (43–145)	34(4–77)	88 (47–147)	<0.001[a]	39 (13–103)	93 (55–150)	<0.001[a]
Cold ischemia time, minutes	298 (258–357)	284 (253–342)	299 (258–359)	0.573[a]	316 (267–375)	294 (257–345)	0.013[a]

HLA eplet mismatch sum	27 (21–33)	27 (21–32)	27 (21–33)	0.857[a]	27 (21–35)	27 (21–33)	0.812[a]
HLA I eplet mismatch sum	17 (12–22)	17 (11–21)	17 (12–22)	0.443[a]	17 (12–23)	17 (12–21)	0.588[a]
HLA II eplet mismatch sum	10 (7–14)	10 (7–14)	10 (7–14)	0.649[a]	10 (7–14)	10 (7–14)	0.895[a]

HLA, human leukocyte antigen; IQR, interquartile range, NASH non-alcoholic steatohepatitis

*The significance of variation was calculated between the outcome groups.

[a]The Mann–Whitney U-test.

[b]The Pearson chi-square test

[c]Includes time to last follow-up date, re-transplantation and death.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 3. Summary statistics of adjusted Cox proportional hazards models for four different missense variant groups.

Endpoint	Missense variants	Cox proportional hazards model			
		Sum of mismatches		Quartiles of mismatches	
		HR (95% CI)	P–value	HR (95% CI)	P–value
Time to acute rejection	All proteins	1.000(0.999–1.001)	0.891	1.003(0.900–1.118)	0.956
	Transmembrane and secreted proteins	1.000(0.998–1.002)	0.820	1.041(0.934–1.161)	0.466
	Transmembrane proteins	1.000(0.998–1.002)	0.787	1.021(0.916–1.138)	0.708
	Liver–related proteins	0.999(0.995–1.003)	0.484	0.985(0.883–1.099)	0.791
Time to late rejection	All proteins	0.998(0.996–0.999)	0.011	0.812(0.674–0.977)	0.028
	Transmembrane and secreted proteins	0.997(0.994–1.000)	0.070	0.890(0.740–1.071)	0.218
	Transmembrane proteins	0.997(0.993–1.001)	0.130	0.859(0.714–1.034)	0.109
	Liver–related proteins	0.994(0.987–1.001)	0.122	0.937(0.779–1.127)	0.489
Time to graft loss	All proteins	0.999(0.997–1.002)	0.657	0.866(0.649–1.156)	0.329
	Transmembrane and secreted proteins	0.996(0.991–1.001)	0.164	0.747(0.559–1.000)	0.050
	Transmembrane proteins	0.995(0.989–1.001)	0.125	0.740(0.551–0.994)	0.046
	Liver–related proteins	1.006(0.995–1.016)	0.297	1.163(0.869–1.556)	0.309
Overall survival	All proteins	0.999(0.998–1.001)	0.226	0.907(0.784–1.049)	0.189
	Transmembrane and secreted proteins	0.999(0.996–1.001)	0.358	0.897(0.777–1.036)	0.138
	Transmembrane proteins	0.999(0.996–1.002)	0.647	0.934(0.809–1.077)	0.348
	Liver–related proteins	0.997(0.991–1.002)	0.271	0.956(0.828–1.105)	0.546

MHC region and sex chromosomes excluded. CI, confidence interval; HR, hazard ratio. Models were adjusted with donor and recipient age, donor and recipient sex, cold ischemia time, HLA I eplet mismatch, HLA II eplet mismatch, year of transplantation, autoimmune liver disease and initial calcineurin inhibitor type.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

4. *cis*-eQTL results of deletion-tagging variants rs11985201, rs2342606, rs2174926, and rs1944862.

FIVEx						
Variant	**CHR:POS**	**Assessed allele**	**Gene**	**Effect size**	**P-value**	**Tissue**
rs2342606	10:80034407	T	TMEM254-AS1	0.18–0.56	1.38×10^{-25}–5.89×10^{-8}	Multiple tissues
rs1944862	11:55521460	G	OR4C6	-0.47	9.12×10^{-13}	LCL
rs11985201	NA	NA	NA	NA	NA	NA
rs2174926	NA	NA	NA	NA	NA	NA
eQTLGen phase I						
Variant	**CHR:POS**	**Assessed allele**	**Gene**	**Z-score**	**P-value**	**Tissue**
rs11985201	8: 39772878	A	IDO1	-5.10	3.32×10^{-7}	Blood
rs2342606	10:81845357	T	TMEM254	-20.46	4.89×10^{-93}	Blood
rs2342606	10:81822642	T	TMEM254-AS1	-16.80	2.49x1063	Blood
rs2342606	10: 81468710	T	FAM22B	10.78	4.18×10^{-27}	Blood
rs2342606	10: 81474464	T	RP11-119F19.2	8.44	3.13×10^{-17}	Blood
rs2342606	10: 82180169	T	FAM213A	7.97	1.65×10^{-15}	Blood
rs2342606	10: 81719933	T	SFTPD	-7.88	3.29×10^{-15}	Blood
rs2342606	10: 82292525	T	RP11-137H2.4	-5.15	2.66×10^{-7}	Blood
rs2342606	10: 81428750	T	RP11-506M13.3	4.95	7.38×10^{-7}	Blood
rs1944862	NA	NA	NA	NA	NA	Blood
rs2174926	NA	NA	NA	NA	NA	Blood

CHR, chromosome; eQTL, expression quantitative loci; LCL, lateral collateral ligament; NA, not available; POS, position.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 5. Identification of regulatory elements.

Deletion-tagging variant	Deleted gene	Regulome DB[a]		HaploReg[b]
		Rank	Score	Regulatory motifs altered
rs11985201	*ADAM3A/ADAM5P*	1b	0.710	INSM1, NF-Y
rs2342606	*LOC642521/LOC642538*	6	0.285	NA
rs2174926	*LOC442434*	1f	0.897	Foxj2, Foxl1, Foxp1
rs1944862	*OR4P1P*	6	0.187	Foxa, ZBTB33

NA, not available.

[a]Regulome DB, https://www.regulomedb.org/regulome-search
[b]HaploReg v4.2, https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. Flow of the study population. Enrolling and exclusion of the liver transplantation recipients and donors. DNA, deoxyribonucleic acid; QC, quality control.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 2. Flow of genetic variants. HLA, human leukocyte antigen; MHC, major histocompatibility complex.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 3. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs11985201 mismatch on acute rejection-free survival.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 4. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs2342606 mismatch on acute rejection-free survival.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 5. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs1944862 mismatch on late rejection-free survival..

medRxiv preprint doi: https://doi.org/10.1101/2024.07.16.24310481; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 6. Kaplan-Meier plot displaying the effect of deletion-tagging variant rs2174926 mismatch on graft loss-free survival.